EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, IONS: Ionis Pharmaceuticals

24 Oct 25 15:59
LAST:

70.83

CHANGE:
 0.64		OPEN:
72.39		HIGH:
72.44		ASK:
53.70		VOLUME:
1.65M
CHG(%):
0.90		PREV:
71.50		LOW:
70.22		BID:
940.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 2572.3972.4470.2270.861.99M
23 Oct 2571.6972.4471.0571.501.61M
22 Oct 2571.2371.9870.6071.501.51M
21 Oct 2572.9473.2070.4771.642.53M
20 Oct 2573.5573.6972.3073.551.4M
17 Oct 2572.9674.0272.3273.091.31M
16 Oct 2573.1274.4272.0773.071.74M
15 Oct 2571.4273.9271.2472.393.23M
14 Oct 2570.5972.1570.0871.371.26M
13 Oct 2570.1671.5069.8470.592.62M

COMPANY PROFILE

Name:Ionis Pharmaceuticals
About:Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Sector:Healthcare
Industry:Biotechnology
Address:2855 Gazelle Court, Carlsbad, CA, United States, 92010
Website:https://www.ionis.com
CUSIP:462222100
CIK:0000874015
ISIN:US4622221004
FIGI:BBG000JH6683
LEI:549300SI4ZGLG0BLUZ92

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:71.811.4%
MA10:71.961.6%
MA20:70.031.1%
MA50:60.9516.2%
MA100:50.6639.8%
MA200:41.2771.6%
STO14:35.04
RSI14:61.53 
WPR14:-58.35
MTM14:1.92
ROC14:0.03 
ATR:1.93 
Week High:74.024.5%
Week Low:70.220.9%
Month High:74.425.1%
Month Low:62.1971.6%
Year High:74.425.1%
Year Low:23.95195.7%
Volatility:16.85 

RECENT DIVIDENDS

Date Amount
17 Feb 2000$0.11
21 Dec 1999$0.11
20 Aug 1999$0.11
21 Jul 1999$0.11
21 Jun 1999$0.11
22 Mar 1999$0.11
17 Feb 1999$0.11